Department of Biochemistry & Molecular Biology and Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA.
Cell Cycle. 2012 Jul 15;11(14):2624-30. doi: 10.4161/cc.20809.
Since the discovery of miRNAs, a number of miRNAs have been identified as p53's transcriptional targets. Most of them are involved in regulation of the known p53 functions, such as cell cycle, apoptosis and senescence. Our recent study revealed miR-1246 as a novel target of p53 and its analogs p63 and p73 to suppress the expression of DYRK1A and consequently activate NFAT, both of which are associated with Down syndrome and possibly with tumorigenesis. This finding suggests that miR-1246 might serve as a likely link of the p53 family with Down syndrome. Here, we provide some prospective views on the potential role of the p53 family in Down syndrome via miR-1246 and propose a new p53-miR-1246-DYRK1A-NFAT pathway in cancer.
自 miRNA 被发现以来,已有许多 miRNA 被鉴定为 p53 的转录靶标。其中大多数参与调节已知的 p53 功能,如细胞周期、细胞凋亡和衰老。我们最近的研究揭示了 miR-1246 作为 p53 及其类似物 p63 和 p73 的一个新靶标,可抑制 DYRK1A 的表达,进而激活 NFAT,两者都与唐氏综合征有关,并且可能与肿瘤发生有关。这一发现表明,miR-1246 可能是 p53 家族与唐氏综合征之间的一个可能的联系。在这里,我们通过 miR-1246 提供了一些关于 p53 家族在唐氏综合征中的潜在作用的前瞻性观点,并提出了癌症中 p53-miR-1246-DYRK1A-NFAT 新途径。